References
- Pagotto U, Marsicano G, Cota D. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Rev. 2006;27:73–100.
- Aggarwhal SK, Carter GT, Sullivan MD, et al. Medical use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5:153–168.
- Lusk SL, Paul TM, Wilson R. The potential impact of the legalization and decriminalization of marijuana on the vocational rehabilitation process. Why the buzz? J Appl Rehab Counsel. 2015;46:3–12.
- Hilliard CJ. Endocannabinoids and the endocrine system in health and disease. In: R. G. Pertwee, editor. Endocannabinoids. New York: Springer; 2015. p. 317–339.
- Alger BE. Getting high on the endocanabinoid system. Cerebrum. 2013;14.
- FDA [Internet]. FDA and Marijuana. [cited 2017 Feb 28]. Available from: https://www.fda.gov/newsevents/publichealthfocus/ucm421163.htm
- AbbVie Inc [Internet]. Why has your healthcare professional prescribed marinol? 2017. Available from: http://marinol.com/
- INSYS Therapeutical Inc [Internet] What is Syndros? 2017. Available from: https://www.syndros.com/
- Meda Pharmaceuticals [Internet]. What is Cessamet? 2017. Available from: http://www.cesamet.com/patient-about-cesamet.asp
- Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part one of two. J. Pain Palliative Care Pharmacother. 2009;23:4–25.
- Pew Research Center [Internet]. Public support for legalizing medical marijuana. [cited 2010 Apr 1]. Available from: http://www.people-press.org/2010/04/01/public-support-for-legalizing-medical-marijuana/
- Pew Research Center [Internet]. Support for marijuana legalization conitnues to rize. [cited 2016 Oct 12]. Available from: http://www.pewresearch.org/fact-tank/2016/10/12/support-for-marijuana-legalization-continues-to-rise/
- The National Academies of Science. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017.
- ADA [Internet]. What is the definition of disability under the ADA? [2017]. Available from: https://adata.org/faq/what-definition-disability-under-ada
- WHO [Internet]. Disabilities. 2017. Available from: http://www.who.int/topics/disabilities/en/
- Smart J. Disability, Society, and the Individual. Gaithersburg (MD): Aspen Publications, Inc; 2001.
- Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Info Libr J. 2009;26:91–108.
- Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.
- Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. Implement Sci. 2010;5:69.
- Ackley BJ, Swan BA, Ladwig G, et al. Evidence-based nursing care guidelines: Medical-surgical interventions. St. Louis (MO): Mosby Elsevier; 2008.
- Pedersen W. From badness to illness: medical cannabis and self-diagnosed attention deficit hyperactivity disorder. Addiction Res Theory. 2015;23:177–186.
- Mitchell JT, Sweitzer MM, Tunno AM, et al. “I use weed for my ADHD”: a qualitative analysis of online forum discussions on cannabis use and ADHD. PLoS One. 2016;11:e0156614.
- Sagar KA, Dahlgren MK, Racine MT, et al. Joint effects: a pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood. PLoS One. 2016;11:e0157060.
- Elliott L, Golub A, Bennett A, et al. PTSD and cannabis-related coping among recent veterans in New York City. Contemporary Drug Problems. 2015;42:60–76.
- Bonn-Miller MO, Babson KA, Vandrey R. Using cannabis to help you sleep: heightened frequency of medical cannabis use among those with PTSD. Drug Alcohol Depend. 2014;136:162–165.
- Bahorik AL, Leibowitz A, Sterling SA, et al. Patterns of marijuana use among psychiatry patients with depression and its impact on recovery. J Affect Disord. 2017;213:168–171.
- Rodríguez-Sánchez JM, Ayesa-Arriola R, Mata I, et al. Cannabis use and cognitive functioning in first-episode schizophrenia patients. Schizophrenia Res. 2010;124:142–151.
- McLoughlin BC, Pushpa-Rajah JA, Gillies D, et al. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014;(10):CD004837.
- Wilsey BL, Deutsch R, Samara E, et al. A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. JPR. 2016;9:587–598.
- Mehta S, McIntyre A, Janzen S, et al. Systematic review of pharmacologic treatments of pain after spinal cord injury: an update. Arch Physical Med Rehabil. 2016;97:1381–1391.
- Arjmand S, Vaziri Z, Behzadi M, et al. Cannabinoids and tremor induced by motor-related disorders: friend or foe?. Neurotherapeutics. 2015;12:778–787.
- Feinstein A, Banwell E, Pavisian B. What to make of cannabis and cognition in MS: in search of clarity amidst the haze. Mult Scler. 2015;21:1755–1760.
- Fernández Ó. THC:CBD in daily practice: available data from UK, Germany and Spain. Eur Neurol. 2016;75:1–3.
- Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. J Neurol. 2006;253:1337–1341.
- Koppel BS. Cannabis in the treatment of dystonia, dyskinesias, and tics. Neurotherapeutics. 2015;12:788–792.
- Patti F. Health authorities data collection of THC:CBD oromucosal spray (L'agenzia italiana del farmaco web registry): figures after 1.5 years. Eur Neurol. 2016;75:9–12.
- Finseth A, Hedeman JL, Brown RP, et al. Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in Colorado. Evidence Based Complement Altern Med. 2015;2015:1.
- Yap M, Easterbrook L, Connors J, et al. Use of cannabis in severe childhood epilepsy and child protection considerations. J Paediatr Child Health. 2015;51:491–496.
- Tzadok M, Uliel-Siboni S, Linder I, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. 2016;35:41–44.
- Treat L, Chapman KE, Knupp KG, et al. Duration of use of oral cannabis extract in a cohort of pediatric epilepsy patients. Epilepsia. 2017;58:123–127.
- Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy—from receptors to clinical response. Epilepsy Behav. 2014;41:277–282.
- Suraev AS, Todd L, Bowen MT, et al. An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy Behav. 2017;70(Pt B):334–340.
- Sivakumar S, Zutshi D, Seraji-Bozorgzad N, et al. Effects of marijuana on ictal and interictal EEG activities in idiopathic generalized epilepsy. J Clin Neurophysiol. 2017;34:e1–e4.
- Saade D, Charuta J. Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report. Pediatr Neurol. 2015;52:544–547.
- Rosenberg EC, Tsien RW, Whalley BJ, et al. Cannabinoids and epilepsy. Neurotherapeutics. 2015;12:747–768.
- Reddy DS, Golub VM. The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther. 2016;357:45–55.
- Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav. 2015;45:49–52.
- O'Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav. 2017;70(Pt B):341–348
- Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55:783–786.
- Ladino LD, Hernández-Ronquillo L, Téllez-Zenteno JF. Medicinal marijuana for epilepsy: a case series study. Can J Neurol Sci. 2014;41:753–758.
- Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57:1617–1624.
- Friedman D, Devinsky O. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2016;374:94–95.
- Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270–278.
- Detyniecki K, Hirsch L. Marijuana use in epilepsy: the myth and the reality. Curr Neurol Neurosci Rep. 2015;15:65.
- Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506–521.
- Belendiuk KA, Baldini LL, Bonn-Miller MO. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:10.
- Russo EB. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 2016;1:154–165.
- Benbadis SR, Sanchez-Ramos J, Bozorg A, et al. Medical marijuana in neurology. Expert Rev Neurother. 2014;14:1453–1465.
- Patel AD. Medical marijuana in pediatric neurological disorders. J Child Neurol. 2016;31:388–391.
- Wilkinson ST, Radhakrishnan R, D’Souza DC. A systematic review of the evidence for medical marijuana in psychiatric indications. J Clin Psychiatry. 2016;77:1050–1064.
- Koppel BS, Brust JCM, Fife T, et al. Review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556–1563.
- Becker H, Roberts G, Morrison J, et al. Recruiting people with disabilities as research participants: challenges and strategies to address them. Mental Retard. 2004;42:471–475.
- Lennox N, Taylor M, Rey-Conde T, et al. Beating the barriers: recruitment of people with intellectual disability to participate in research. J Intellect Disabil Res. 2005;49:296–305.
- WHO [Internet] World Report on Disability. 2011. Available from: http://www.who.int/disabilities/world_report/2011/report/en/
- Goering S. Rethinking disability: the social model of disability and chronic disease. Curr Rev Musculoskelet Med. 2015;8:134–138.